Attached files

file filename
10-Q - FORM 10-Q - ACHILLION PHARMACEUTICALS INCd230843d10q.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex322.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex312.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex321.htm
EXCEL - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR17.htm
v2.3.0.15
Statements Of Cash Flows (USD $)
In Thousands
9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Cash flows from operating activities  
Net loss$ (31,821)$ (19,237)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation and amortization236539
Noncash stock based compensation1,9841,459
Noncash interest expense939
(Gain) loss on disposal of equipment(110)6
Amortization of premium on marketable securities351169
Changes in operating assets and liabilities:  
Accounts receivable153(26)
Prepaid expenses and other assets129(1,218)
Accounts payable1,396414
Accrued expenses2,021(293)
Net cash used in operating activities(25,652)(18,148)
Cash flows from investing activities  
Purchases of fixed assets(593)(154)
Purchases of marketable securities(72,875)(39,700)
Maturities of marketable securities35,6945,050
Net cash used in investing activities(37,774)(34,804)
Cash flows from financing activities  
Proceeds from sale of common stock, net of issuance costs60,94772,556
Proceeds from exercise of stock options511 
Proceeds from sale of common stock under Employee Stock Purchase Plan7550
Payment of deferred financing costs(18) 
Borrowings of debt438 
Repayments of debt(512)(1,682)
Net cash provided by financing activities61,44170,924
Net increase in cash and cash equivalents(1,985)17,972
Cash and cash equivalents, beginning of period25,3739,712
Cash and cash equivalents, end of period23,38827,684
Supplemental disclosure of cash flow information  
Cash paid for interest$ 20$ 184